Comparative Pharmacology
Head-to-head clinical analysis: CARMOL HC versus VANOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARMOL HC versus VANOS.
CARMOL HC vs VANOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carmol HC is a combination of urea (a keratolytic) and hydrocortisone (a corticosteroid). Urea softens and dissolves the intercellular matrix of the stratum corneum, promoting desquamation and enhancing penetration of hydrocortisone. Hydrocortisone suppresses inflammation by induction of phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
VANOS (fluocinonide 0.1% cream) is a corticosteroid that binds to glucocorticoid receptors, leading to inhibition of phospholipase A2 and reduction of prostaglandin and leukotriene synthesis, resulting in anti-inflammatory, antipruritic, and vasoconstrictive effects.
Apply a thin film to affected area twice daily; topical, not for ophthalmic or oral use.
Apply a thin layer to affected areas once or twice daily. Not for use longer than 2 weeks; maximum 15 g per day.
None Documented
None Documented
1-2 hours (hydrocortisone acetate); clinical effects persist longer due to local anti-inflammatory action; tissue half-life not well defined.
The terminal elimination half-life is approximately 7.5 hours (range 5-12 hours). This supports twice-daily or once-daily dosing for sustained local effect.
Primarily renal excretion of metabolites (40-60%) as glucuronide and sulfate conjugates; <10% unchanged; biliary/fecal elimination accounts for <20%.
Primarily renal excretion (glucuronidation and sulfation); minimal biliary elimination (<5%). Approximately 60-70% of the dose is excreted in urine as metabolites, with <1% unchanged.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid